Updated clinical practice guidelines for the management of adult diffuse gliomas

作者：Tao Jiang, Do‐Hyun Nam, Zvi Ram, Wai-Sang Poo, Jiguang Wang, Damdindorj Boldbaatar, Ying Mao, Wenbin Ma, Qing Mao, Yongping You, Chuanlu Jiang, Xuejun Yang, Vinay Tergaonkar, Wei Zhang, Zheng Wang, Chunsheng Kang, Xiaoguang Qiu, Shaowu Li, Ling Chen, Xuejun Li, Zhixiong Liu, Hongmin Bai, Yu Yao, Shouwei Li, Anhua Wu, Yonggao Mou, Ke Sai, Guilin Li, Xinting Wei, Xianzhi Liu, Zhiwen Zhang, Yiwu Dai, Shengqing Lv, Liang Wang, Zhixiong Lin, Jun Dong, Guozheng Xu, Xiaodong Ma, Rutong Yu, Dezhi Kang, Yanhui Liu, Gang Li, Shizhong Zhang, Yan Qu, Yang Wang, Chuanbao Zhang, Baoshi Chen, Gan You, Yongzhi Wang, Yinyan Wang, Zhaoshi Bao, Xing Fan, Xing Liu, Zheng Zhao, Yiming Li, Zhiliang Wang, Guanzhang Li, Shengyu Fang, Yanwei Liu, Xia Shan, Yuqing Liu, Ruichao Chai, Huimin Hu, Jing Chen, Wei Yan, Jinquan Cai, Yu Wang · 发表于：Cancer Letters · 年份：2025 · DOI：10.1016/j.canlet.2025.218185 · 被引用次数：14 · 研究领域：Glioma Diagnosis and Treatment、Clinical practice guidelines implementation、Brain Metastases and Treatment

It has been five years since the last version of the clinical practice guidelines for the management of adult diffuse gliomas was published by the Asian Glioma Genome Atlas (AGGA). Significant progress and revisions have occurred in the diagnosis and treatment of adult diffuse gliomas in recent years. In response to these updates, the joint guideline committee of the Chinese Glioma Cooperative Group (CGCG), the Society for Neuro-Oncology of China (SNO-China), and the Chinese Brain Cancer Association (CBCA) has revised the clinical practice guidelines. This updated guideline emphasizes molecular and pathological diagnostics, as well as the primary treatment modalities of surgery, radiotherapy, chemotherapy, and targeted therapy. Additionally, we have incorporated findings from recent clinical trials of new therapies to align with cutting-edge treatment strategies. This guideline is designed to serve as a practical resource for all professionals involved in managing adult diffuse glioma patients, while also providing valuable information for insurance companies and other institutions responsible for regulating cancer care costs in China and beyond.